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Background
The Cross-Canada Anaphylaxis Registry (C-CARE) aims
to examine burden, triggers, management and temporal
trends in anaphylaxis.
Methods
Over a three-year period (April 2011 to April 2014), data
were collected on anaphylaxis cases at the Montreal Chil-
dren’s Hospital emergency department (ED). Cases were
recruited either prospectively or identified retrospectively
based on chart review through ICD10 codes related to
anaphylaxis. Logistic regressions were conducted to
determine the association between sociodemographic
and clinical characteristics and development of severe
reactions as well as epinephrine use.
Results
Among 624 cases the median age was 5.7 years (IQR
2.4-11.7) and the majority (56.6%) were males. The per-
centage of anaphylaxis among all ED visits increased
from 0.22% (95% CI 0.18%, 0.24%) in 2011 to 0.3% (95%
CI 0.25%, 0.33%) in 2014, yielding a difference of 0.08%
(95%CI, 0.03%, 0.13%). The major trigger was food
(81.4%), mainly peanut and tree-nut. Most cases were
moderate (70.2%) (breathing difficulties, stridor, diar-
rhea, crampy abdominal pain, recurrent vomiting).
Of all reactions 28.7% were not administered epinephr-
ine. Almost 95% were prescribed or had an epinephrine
auto-injector (71.6% Epipen , 22.7% Allerject).
Factors associated with severe reactions included his-
tory of peanut allergy, asthma and steroid treatment in
ED. (Table 1).
Management of anaphylaxis with at least one dose of
epinephrine was associated with known food allergy and
use of steroids in ED.
Administration of two or more epinephrine doses in
ED was less likely in those who received epinephrine
outside ED and more likely with severe reactions, reac-
tions triggered by tree-nut and in those treated with
steroids in ED.
Conclusions
The percentage of anaphylaxis cases among all ED visits
increased by almost 40% over a three-year period. Prompt
use of epinephrine may prevent use of subsequent
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Table 1 Logistic regressions assessing severe reactions
and use of epinephrine
Severe reactions
Variable OR, 95%CI
Asthma 2.3 (1. 5)
Use of steroids in ED 2.5 (1.2, 5.2)
Peanut allergy 2.2 (1, 4.9)
No use of epinephrine
Use of steroids in ED 0.2 (0.1, 0.4)
Known food allergy 0.3 (0.2, 0.5)
Use of more than 2 epinephrine in ED
Use of epinephrine outside 0.06 (0.01, 0.6)
Use of steroids in ED 9.0 (2.6, 31)
Severe reaction 16.8 (4.7, 61)
Tree-nut allergy 5.4 (1.2, 24)
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multiple doses of epinephrine in ED. Reactions triggered
by tree-nut are more prone to require treatment with mul-
tiple doses of epinephrine.
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